Molecular radiotherapy developer Theragnostics said it has signed an intellectual property agreement with AstraZeneca.
The agreement allows Theragnostics to develop radiotherapy based on radionuclide-labeled poly (ADP-ribose) polymerase (PARP) inhibitors, a class of oncology drugs that block the PARP enzyme, which cancer cells use in response to DNA damage.Theragnostics inks AstraZeneca agreement
Latest in Radiation Oncology/Therapy
Could more imaging access improve prison cancer care?
October 15, 2025
Elekta releases report on radiotherapy's role in cancer care
October 9, 2025
PSMA PET-guided radiotherapy shows promise
October 3, 2025
Accuray partners with UW-Madison
October 1, 2025